MediWound Ltd. (MDWD)

NASDAQ: MDWD · IEX Real-Time Price · USD
2.94 0.05 (1.73%)
Jan 18, 2022 1:58 PM EST - Market open
Market Cap80.11M
Revenue (ttm)24.95M
Net Income (ttm)-11.12M
Shares Out27.25M
EPS (ttm)-0.41
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume97,741
Open2.77
Previous Close2.89
Day's Range2.77 - 3.11
52-Week Range2.20 - 6.22
Beta1.53
AnalystsStrong Buy
Price Target6.92 (+135.3%)
Earnings DateNov 16, 2021

About MDWD

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MWPC005, a topically applied biological dr...

IndustryPharmaceuticals
IPO DateMar 20, 2014
CEOSharon Malka
Employees75
Stock ExchangeNASDAQ
Ticker SymbolMDWD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for MediWound stock is "Strong Buy." The 12-month stock price forecast is 6.92, which is an increase of 135.26% from the latest price.

Price Target
$6.92
(135.26% upside)
Analyst Consensus: Strong Buy

News

MediWound Announces Positive Initial Data from its U.S. Phase 2 Pharmacology Study of EscharEx Showing Effective and ...

Data Demonstrate EscharEx Reduces Biofilm and Bacterial Burden EscharEx is Shown to be Safe with No Observed Safety Issues

4 weeks ago - GlobeNewsWire

MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study

Topline Data Expected in the First Quarter of 2022 Topline Data Expected in the First Quarter of 2022

1 month ago - GlobeNewsWire

EMA Provides Regulatory Path for Pediatric Label Extension for NexoBrid

Anticipate Submission for Label Extension in First Half 2022 Anticipate Submission for Label Extension in First Half 2022

2 months ago - GlobeNewsWire

MediWound (MDWD) Reports Q3 Loss, Tops Revenue Estimates

MediWound (MDWD) delivered earnings and revenue surprises of 0.00% and 13.79%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

MediWound Reports Third Quarter 2021 Financial Results

Third Quarter Revenues of $6.4 Million ; Year-to-Date 2021 Revenues Increased 21%

2 months ago - GlobeNewsWire

Earnings Preview For MediWound

MediWound (NASDAQ:MDWD) is set to give its latest quarterly earnings report on Tuesday, 2021-11-16. Here's what investors need to know before the announcement.

2 months ago - Benzinga

MediWound to Report Third Quarter 2021 Financial Results and Host a Conference Call and Webcast on November 16, 2021

YAVNE, Israel, Nov. 04, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and re...

2 months ago - GlobeNewsWire

Analysts Estimate MediWound (MDWD) to Report a Decline in Earnings: What to Look Out for

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

MediWound Announces Peer-Reviewed Publication of EscharEx In-Vivo Head-to-Head Comparator Study in the Journal of Wou...

EscharEx Treatment Demonstrated Superior Efficacy in Debridement of Eschar EscharEx Treatment Demonstrated Superior Efficacy in Debridement of Eschar

3 months ago - GlobeNewsWire

MediWound to Present at Upcoming Investor Conferences

YAVNE, Israel, Sept. 03, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tiss...

4 months ago - GlobeNewsWire

MediWound (MDWD) Reports Q2 Loss, Tops Revenue Estimates

MediWound (MDWD) delivered earnings and revenue surprises of -9.09% and 6.36%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

MediWound Reports Second Quarter Financial Results

Second Quarter Revenues of $6.1 Million - Increase of 50% Year-over-Year

5 months ago - GlobeNewsWire

MediWound to Report Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 10, 2021

YAVNE, Israel, Aug. 02, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and re...

5 months ago - GlobeNewsWire

Will MediWound (MDWD) Report Negative Q2 Earnings? What You Should Know

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

MediWound Starts Testing MW005 In Two Mid-Stage Trials In Patients With Non-Melanoma Skin Cancer

MediWound Ltd (NASDAQ: MDWD) has initiated a Phase 1/2 study of MW005 to treat low-risk Basal Cell Carcinoma (BCC).  In parallel, an investigator-initiated Phase 2 trial of MW005 in non-melanoma skin ca...

5 months ago - Benzinga

MediWound's NexoBrid Shows Significant Beneficial Impact On Pediatric Burn Patients

MediWound Ltd (NASDAQ: MDWD) has announced topline results from Phase 3 pediatric study with NexoBrid to treat severe thermal burns.  The 145-subject study met its three primary endpoints.

5 months ago - Benzinga

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MediWound Ltd. - MDWD

NEW YORK, July 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MediWound Ltd. ("MediWound" or the "Company") (NASDAQ: MDWD).

6 months ago - PRNewsWire

MediWound Announces Peer-Reviewed Paper Detailing EscharEx Phase 2 Randomized Control Trial Results Published in the ...

Study Findings D emonstrate S trong R esults in Debriding V enous L eg U lcers and D iabetic F oot U lcers

6 months ago - GlobeNewsWire

Why Shares Of MediWound And Vericel Fell On Tuesday

Shares of MediWound (NASDAQ: MDWD) and its development partner, Vericel Corporation (NASDAQ: VCEL), are trading lower after MediWound received a Complete Response Letter from the FDA for its NexoBrid Bi...

Other symbols:VCEL
6 months ago - Benzinga

FDA Strikes Off MediWound - Vericel's NexoBrid Biologics License Application; Stocks Drop

Vericel Corporation's (NASDAQ:VCEL) development partner, MediWound Ltd (NASDAQ:MDWD), received a complete response letter from FDA regarding the NexoBrid application seeking approval for eschar removal ...

Other symbols:VCEL
6 months ago - Benzinga

MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License Application

Company Remains Committed to Working with FDA Toward a Potential Approval for this Important Therapy Company Remains Committed to Working with FDA Toward a Potential Approval for this Important Therapy

6 months ago - GlobeNewsWire

Best Penny Stocks To Buy Now? 7 To Watch This Week

What are the best penny stocks to buy this week? The post Best Penny Stocks To Buy Now?

Other symbols:AEZSAMRNDRRXGLBSLOTZ
6 months ago - PennyStocks

MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study

Interim Assessment Expected by end of July 2021 and Completion of Enrollment by Year-End 2021 Interim Assessment Expected by end of July 2021 and Completion of Enrollment by Year-End 2021

7 months ago - GlobeNewsWire

MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates

MediWound (MDWD) delivered earnings and revenue surprises of 16.67% and 10.32%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research